2023
Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis
Dyckhoff-Shen S, Bewersdorf J, Teske N, Völk S, Pfister H, Koedel U, Klein M. Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis. Infection 2023, 52: 219-229. PMID: 37656347, PMCID: PMC10811117, DOI: 10.1007/s15010-023-02087-8.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid pleocytosisCerebrospinal fluid cell countBacterial meningitisCerebrospinal fluidCNS infectionCell countElevated white blood cell countResultsThe most common etiologyMethodsA retrospective cohort studyNeoplastic diseaseAutoimmune CNS diseaseWhite blood cell countRetrospective cohort studySpectrum of patientsCharacteristics of patientsBlood cell countCerebrospinal fluid proteinAbnormal mental statusLaboratory featuresCSF pleocytosisCSF leukocytesLaboratory parametersClinical presentationNuchal rigidityCommon etiologiesConsensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Zeidan A, Platzbecker U, Bewersdorf J, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway H, Daver N, Díez-Campelo M, de Witte T, DeZern A, Efficace F, Garcia-Manero G, Garcia J, Germing U, Giagounidis A, Griffiths E, Hasserjian R, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj A, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht A, Wei A, Sekeres M, Fenaux P. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood 2023, 141: 2047-2061. PMID: 36724453, DOI: 10.1182/blood.2022018604.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk MDSComplete remissionResponse criteriaInternational Working GroupClinical trialsHigh-risk myelodysplastic syndromeEnd pointMarrow complete remissionPartial hematologic recoveryClinical end pointsPatient-centered outcomesNovel investigational drugsVariable clinical presentationEvent end pointsHemoglobin thresholdHematologic recoveryCount recoveryClinical presentationClinical benefitMyelodysplastic syndromeIWG criteriaMyelodysplastic neoplasmsConsensus recommendationsInvestigational drugsNew agents
2018
Challenges in HSV encephalitis: normocellular CSF, unremarkable CCT, and atypical MRI findings
Bewersdorf J, Koedel U, Patzig M, Dimitriadis K, Paerschke G, Pfister H, Klein M. Challenges in HSV encephalitis: normocellular CSF, unremarkable CCT, and atypical MRI findings. Infection 2018, 47: 267-273. PMID: 30506479, DOI: 10.1007/s15010-018-1257-7.Peer-Reviewed Original ResearchConceptsHSV encephalitisCerebrospinal fluidLevel of clinical suspicionCerebrospinal fluid cell countSpectrum of clinical presentationsMagnetic resonance imaging abnormalitiesSevere brainstem involvementTemporal lobe hemorrhageTreated with acyclovirFocal neurological deficitsLife-saving therapyAcyclovir therapyClinical suspicionBrainstem involvementAtypical presentationClinical presentationAtypical findingsDiagnostic challengeClinical featuresDelayed administrationLaboratory findingsClinical outcomesCT scanSimplex virusNeurological deficits